This increases expression of EGFR, conferring treatment resistance and cell longevity, as exemplified in a study on HNSCC cell lines by Boeckx et al.,49 in which increased cetuximab sensitivity was noted in a cell line exposed to hypoxia for 72 h. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.